8-K: Indivior PLC Shareholders Approve Scheme of Arrangement
Corporate Restructuring Update
Indivior PLC shareholders overwhelmingly approved a scheme of arrangement and related amendments to the company's articles of association, paving the way for its re-domiciliation.
Summary
- Shareholders of Indivior PLC approved amended and restated articles of association on December 11, 2025.
- The amendments introduce a new Article 136 to facilitate a scheme of arrangement, ensuring all Indivior PLC shareholders become shareholders of Indivior Pharmaceuticals, Inc.
- The scheme aims to make Indivior PLC a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc.
- A Court Meeting approved the Scheme of Arrangement with 15 shareholders voting for (representing 94,968,161 votes) and 2 against (representing 46,544 votes).
- An Extraordinary General Meeting passed six special resolutions, including authorizing directors to effect the scheme, reduce share capital, allot new shares, amend articles, re-register as a private company, and adopt Post-Scheme Articles of Association.
- Completion of the Scheme remains subject to sanction by the High Court of Justice in England and Wales, with a hearing expected on January 22, 2026.
Sentiment
Score: 8
Explanation: The filing indicates successful progress on a significant corporate restructuring with overwhelming shareholder approval, suggesting strong internal alignment and a clear path forward for the strategic initiative. The only remaining step is court sanction, which is a procedural formality after shareholder approval.
Positives
- Overwhelming shareholder approval for the Scheme of Arrangement and related resolutions, indicating strong support for the corporate restructuring.
- The new Article 136 ensures that all shares issued before the Scheme Record Time are subject to the Scheme, providing certainty for the transition.
- The successful passage of resolutions facilitates the strategic objective of Indivior PLC becoming a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc.
Risks
- Completion of the Scheme of Arrangement remains subject to the sanction of the High Court of Justice in England and Wales.
Future Outlook
The Scheme of Arrangement is expected to be completed later in January 2026, following the sanction hearing by the High Court of Justice in England and Wales scheduled for January 22, 2026. This will result in Indivior PLC becoming a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc., with all Indivior PLC shareholders transitioning to become shareholders of Indivior Pharmaceuticals, Inc.
Industry Context
This corporate restructuring, often referred to as a re-domiciliation or scheme of arrangement, is a strategic move for companies to optimize their legal and operational structure, potentially for tax efficiency, market access, or to align with a new parent entity. Such actions are common in the pharmaceutical industry for global companies seeking to streamline their international operations.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendments to Articles of Association | Shareholders approved amended and restated articles of association, including a new Article 136 to facilitate the Scheme of Arrangement. This article ensures that any ordinary shares allotted and issued after the Amended Articles take effect but before the Scheme Record Time are subject to the terms of the Scheme. | 2025-12-11 | Provides legal certainty for the corporate restructuring, ensuring all shareholders are bound by the Scheme and facilitating the transition of Indivior PLC into a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. |
| Share Capital Reduction Authorization | Shareholders authorized the reduction of share capital as part of the Scheme of Arrangement. | 2025-12-11 | A necessary step for the corporate restructuring, likely related to the re-domiciliation and becoming a subsidiary. |
| Re-registration as Private Company Authorization | Shareholders authorized the re-registration of the Company as a private company limited by shares. | 2025-12-11 | Directly supports the objective of Indivior PLC becoming a wholly-owned subsidiary, as private companies have fewer public reporting requirements. |
| Adoption of Post-Scheme Articles of Association Authorization | Shareholders authorized the adoption of the Post-Scheme Articles of Association. | 2025-12-11 | Ensures the company's governance documents are aligned with its new corporate structure as a private, wholly-owned subsidiary. |
Legal Proceedings
- The Scheme of Arrangement requires sanction by the High Court of Justice in England and Wales, with a hearing expected on January 22, 2026.
Stakeholder Impact
- Shareholders: Indivior PLC shareholders will become shareholders of Indivior Pharmaceuticals, Inc.
- Company Structure: Indivior PLC will become a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc.
Next Steps
- High Court of Justice hearing for sanction of the Scheme of Arrangement on January 22, 2026.
- Expected completion of the Scheme of Arrangement later in January 2026.
Key Dates
| Date | Description |
|---|---|
| 2025-11-07 | High Court of Justice order convening the Court Meeting. |
| 2025-11-14 | Shareholder circular published regarding the Scheme of Arrangement. |
| 2025-12-11 | Shareholders approved amended and restated articles of association; Amended Articles became effective; Court Meeting and Extraordinary General Meeting held. |
| 2025-12-15 | Date of signing of the 8-K report by CFO Ryan Preblick. |
| 2026-01-22 | Expected date of High Court of Justice hearing for sanction of the Scheme of Arrangement. |
| 2026-01-31 | Expected completion of the Scheme of Arrangement (later in January 2026). |
Keywords
Indivior PLC, Scheme of Arrangement, Corporate Restructuring, Shareholder Vote, Articles of Association, SEC Filing, Corporate Governance, INDV, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.